Background: De novo non-alcoholic fatty liver disease (NAFLD) in liver-transplanted
| INTRODUCTION
In the last decades, the increasing prevalence of obesity and diabetes has brought attention to the hepatic manifestation of metabolic syndrome, that is, liver steatosis. 1 With the gradual reduction in virus-related liver disease in the Western countries, non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH), is currently one of the most common chronic liver diseases and is caused by fatty acids' accumulation in hepatocytes, leading to different degrees of liver damage, from benign steatosis to decompensated cirrhosis. 1 Their incidence is growing, in both adults and children, so that NASH is expected to become the most important cause of cirrhosis and the first indication for liver transplantation. 2 In the USA, recent studies have estimated that up to 30%-40% of dysmetabolic adults have NAFLD and 3%-5% suffer from NASH. 3 Currently, in the UNOS registry (data as of 7 September 2017), 4 NASH represents the primary indication for liver transplantation in 13.6%
of recipients, a considerably greater percentage than in the past years (9.7% in 2009). Furthermore, some authors demonstrated that many patients who were diagnosed with cryptogenic cirrhosis in the past years had actually histological features of NASH. 5 The widespread diffusion of NAFLD could potentially have important consequences both on liver donors, since graft steatosis is related to primary nonfunction or dysfunction, and recipients, who are frequently affected by metabolic syndrome, although overall survival in these patients is comparable with non-NAFLD recipients. 6 In liver transplantation recipients, the prevalence of cardiovascular risk factors, such as obesity, diabetes and dyslipidaemia, is increased compared to the general population although it can be partially attributed to immunosuppressive drugs (steroids, calcineurin inhibitors). 7, 8 Therefore, we can hypothesise that NAFLD can be quite common among these patients. Post-transplant recurrence of NAFLD is estimated at 24%-45%, according to the methodology used for the diagnosis (biopsy, ultrasound or biochemistry), although patient and graft survival at 1, 5 and 10 years are similar to recipients without NAFLD recurrence and to those with different indications for liver transplantation. 9 De novo NAFLD is defined as the occurrence of liver steatosis or steatohepatitis in recipients (at least 6 months after transplantation) who were transplanted for indications other than NASH. In different studies, its prevalence is reported between 18% and 33% and is mainly related to diabetes, hypertension, obesity, hyperlipidaemia, alcohol-related cirrhosis and tacrolimus use. 10 The actual impact of de novo NAFLD and NASH in transplant recipients is still not known. Herein, we performed a systematic review and evaluated the prevalence of de novo NAFLD in liver transplantation recipients and possible associated factors.
2 | ME TH ODS
| Eligibility criteria and study selection
Methods of analysis and inclusion criteria were based on "Preferred
Reporting Items for Systematic reviews and Meta-Analyses" (PRISMA) recommendations. 11 We excluded review articles, experimental in vitro studies, studies investigating recurrent steatosis after liver transplantation for NASH and single case reports. 
| Prevalence of de novo NAFLD in liver transplantation
De novo NAFLD after liver transplantation was found in 524 of the 2166 patients enrolled across all 12 studies, with percentages between 14.7% and 52% ( Table 1) . As reported in Figure 2 , the mean-weighted prevalence was the 26%, with a 95% CI of 20%-31%.
| Prevalence of de novo NASH in liver transplantation
Only eight studies assessed histologically the presence of NASH in transplanted patients, [15] [16] [17] 19, 20, [22] [23] [24] with rates ranging from 0.96% to 32%. The pooled prevalence of NASH was the 2% (95% CI 0%-3%). The forest plot of the analysis is displayed in Figure 3 . In the group of patients transplanted for HBV chronic hepatitis, the mean prevalence of de novo NAFLD was the 22% (95% CI 12%-32%), being observed in 56 of 242 cases. Post-liver transplantation steatosis was found in 123 of 333 patients whose indication for liver transplantation was alcoholic cirrhosis. The pooled prevalence was the 37% (95% CI 27%-47%).
Records identified
If we consider subjects transplanted for cholestatic disordersprimary biliary cholangitis and primary sclerosing cholangitis-de novo NAFLD was overall found in only 17 of 151 cases, with a low pooled prevalence of 7% (95% CI 0%-15%).
Only nine patients were transplanted for autoimmune hepatitis, and two of these underwent post-liver transplantation steatosis (mean prevalence of 40%).
Only two cases of transplantation for Wilson disease was found, which did not develop post-liver transplantation NAFLD.
In the group of patients transplanted for acute liver failure (29 subjects), de novo steatosis was recorded in 11 of them, with a mean prevalence of 36% (95% CI 3%-68%).
Eighty-six liver-transplanted patients had a concomitant hepatocellular carcinoma. In this subset of patients, post-liver transplantation NAFLD was observed in 16 of them. The pooled prevalence was 18%, with a 95% CI 2%-34%. No study specified the association between hepatocellular carcinoma and underlying primary liver disease.
Finally, de novo post-liver transplantation steatosis was found in 133 of 385 cases of cryptogenic cirrhosis, with a pooled prevalence of 35% (95% CI 26%-44%).
The forest plots of such analyses are summarised in Figure 4 .
| de novo NAFLD according to immunosuppressive regimen
The prevalence of de novo post-liver transplantation NAFLD according to immunosuppressive drugs was reported in only five studies. [15] [16] [17] 24, 26 The corresponding results and plots are reported in Figure 5 .
In the group of patients receiving tacrolimus, 159 of 601 experienced de novo post-liver transplantation steatosis, with a pooled
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prevalence of 26% (95% CI 20%-33%). Of 398 liver-transplanted patients, 103 assuming ciclosporin had NAFLD, with a mean prevalence of 31% (95% CI 13%-49%). A total of 246 subjects received corticosteroids at the time of biopsy, and in 60 of them, liver steatosis was detected; the pooled prevalence of de novo NAFLD in the corticosteroid group was 24% (95% CI 11%-37%). Data about azathioprine were available in two studies, with a weighted prevalence of 23% (95% CI 0%-46%). No study reported the prevalence of NAFLD when combined immunosuppressive regimen was adopted.
A direct comparison of the prevalence of NAFLD between patients under tacrolimus vs ciclosporin was possible in three studies. 15, 16, 24 The prevalence was 22.6% and 24.3%, respectively.
Therefore, we found an OR = 1.02, with a 95% CI 0.3-3.51, P = 0.98, meaning that both drugs share a similar risk in inducing NAFLD ( Figure 6) . A random effects model was chosen. We found high heterogeneity (v 2 = 16.3, P = 0.0003).
| DISCUSSION
The growing epidemic of obesity and metabolic syndrome has led to increasing rates of cardiovascular and metabolic disorders. It has been observed that patients undergoing liver transplantation are more prone to experience metabolic complications such as diabetes, hypertension or dyslipidaemia. 27, 28 NAFLD may be an important element in the spectrum of metabolic syndrome and, especially when it evolves into NASH and cirrhosis, it can become an indication to liver transplantation. 29, 30 Indeed, the growing percentage of patients transplanted for NASH seems to parallel the spreading of obesity. 31, 32 When NASH is the primary indication to liver transplantation, the reappearance of liver steatosis is a well-known phenomenon.
Bhagat et al 33 26%, a figure that is similar to the prevalence in healthy population (about 22% in a recent experience 38 ).
In the subanalysis reported in Figure 4 , we found that alcoholic and cryptogenic cirrhosis are related to the highest prevalence of de novo NAFLD, respectively, the 37% and the 35%. Such findings are in perfect agreement with data from literature. It is well-known indeed that ethanol consumption may cause excessive reactive oxygen species and subsequent lipid peroxydation in the liver. 39 Moreover, chronic ethanol administration could enhance hepatic influx and uptake of free fatty acids released from adipose tissue and, finally, alcoholic cirrhosis is often accompanied by hyperlipidaemia, which in turn may worsen steatosis. 40, 41 In the case of cryptogenic cirrhosis, an unrecognised NASH may often hide behind. [42] [43] [44] [45] Therefore, post-liver transplantation NAFLD could represent just a relapse of the original disease, thus explaining the high prevalence of steatosis in cryptogenic cirrhosis. 46 On the other hand, most of studies have demonstrated that patients infected with HCV show very high NAFLD comorbidity, close to 55%. 47 This finding could be related to a direct atherogenic effect of the virus, which may endorse insulin resistance by itself. 48, 49 However, many other studies have provided contradictory results. Indeed, subjects with chronic HCV infection often present hypocholesterolaemia due to the fact that enzymes involved in viral replication compete with the genesis of intracellular lipid droplets. 50 Moreover, patients with HCV-related cirrhosis may simultaneously encounter alcohol abuse, thus explaining the high prevalence of steatosis. 51 In conclusion, such controversial findings may explain our results that, when the indication to liver transplantation is HCV, the prevalence of de novo steatosis is low.
Autoimmune cholestatic disorders are frequently associated to dyslipidaemia, thus explaining the high coexistence of NAFLD. 52 Moreover, it has been demonstrated that bile duct injury and senescence of cholangiocytes in primary biliary cholangitis may produce a progression in NAFLD-associated fibrosis. 53 Nevertheless, it may be argued that primary biliary cholangitis-NAFLD is a false association,
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Contos (2001) Dumortier (2010) Kim (2014) Lim (2007) Ong (2001) Seo (2007) Vallin (2014) Yalamanchili ( Dumortier (2010) Dumortier (2010) Karam (2016) Karam (2016) Ong (2001) Kim ( 61 found that the diabetogenic effects of tacrolimus and ciclosporin were analogous. Similarly, another study showed similar lipid blood pattern and glycaemic control between tacrolimus and ciclosporin. 62 On the contrary, a follow-up study of 26 patients over 8 months post-liver transplantation found an improvement in hypercholesterolaemia, body weight and hypertension when patients were switched from ciclosporin to tacrolimus. 63 Consequently, it appears that there is no consensus on this topic. Herein, we reported a rate of steatosis of 26% for tacrolimus and 31% for ciclosporin ( Figure 5 ), and we demonstrated that there was no significant difference between the two calcineurin inhibitors in increasing the risk of de novo NAFLD ( Figure 6 ).
Some limitations should be underlined. First, the heterogeneity between studies is a major concern. The timing of liver biopsy sampling varies between studies, and it is known that a recently transplanted graft may show a different histological condition than another one transplanted many years before the sampling, since many factors (diet, length of immunosuppression, rejection episodes, disease recurrence) could modulate microscopic remodelling of the liver.
However, included studies did not provide sufficient data to perform a subanalysis according to the timing of liver biopsy. Other limitations of the present analysis are the retrospective nature of included studies, the fact that no data about disease recurrence in the graft have been provided and the inclusion of patients transplanted both recently and at the early 90s. Unfortunately, these elements could not be enclosed in the analysis; therefore, we did not investigate whether they could impact on the evolution of de novo steatosis.
In conclusion, the results of our analysis arise some important considerations. The prevalence of post-liver transplantation de novo NAFLD is similar to the general population, and some risk factors such as the aetiology of liver disease may be advocated. Of note, the reported prevalence of NAFLD in general population 38 takes into account the whole previous clinical history of enrolled patients, while, in our study, the onset of NAFLD dates back to the act of transplantation; therefore, it may be argued that its development is more rapid than in the general population. Nevertheless, lack of information about steatosis of the graft is an important drawback. In the studies reporting the steatosis of the graft, we found a rate of about 20%-30%, very similar to the prevalence in the post-transplantation group.
However, due to the lack of data, we cannot discriminate whether the de novo NAFLD have arisen in grafts already with steatosis, or NAFLD occurred in livers with no signs of fat deposition at the time of transplantation. Both hypotheses are plausible. Finally, the heterogeneity of studies and their retrospective nature are a limit in our review. Further studies, mainly planned prospectively, would shed a new light on this issue and allow more precise and evidence-based considerations.
Nonetheless, a note of caution should be applied in transplanted patients, since the high obesity rate translates into a more severe impact on metabolism and NAFLD, thus causing an increase in mortality for both cardiovascular events and reduced graft survival.
64-67

ACKNOWLEDG EMENTS
Declaration of personal interests: We thank Vito Bellomo for graphical assistance.
Declaration of funding interests: None.
AUTHORSHIP
Guarantor of the article: Di Leo A. 
